Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Osaka
Clinical trial register · Japan

Clinical Trials in Osaka, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Fukuoka 557 Nagoya 513 Sapporo 400 Tokyo 375 Osaka 354
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline19 AstraZeneca18 Eli Lilly and Company17 Pfizer16 Novartis Pharmaceuticals14 AbbVie14 Hoffmann-La Roche12 Janssen Research & Development, LLC12 Merck Sharp & Dohme LLC11 Takeda9 Daiichi Sankyo8 Bristol-Myers Squibb7 Ono Pharmaceutical Co., Ltd.7 BioMarin Pharmaceutical6 Novo Nordisk A/S6 Gilead Sciences6 Amgen6 Otsuka Pharmaceutical Co., Ltd.5 Taiho Pharmaceutical Co., Ltd.5 ViiV Healthcare4 Sanofi4 Alexion Pharmaceuticals, Inc.3 W.L.Gore & Associates3 Kite, A Gilead Company3 Incyte Corporation3 Show all 135
Site location
Fukuoka557 Nagoya513 Sapporo400 Tokyo375 Osaka354 Chiba328 Kashiwa317 Yokohama272 Kobe239 Kyoto231 Hiroshima224 Sendai207 Chūōku202 Matsuyama172 Bunkyō City171 Kanazawa149 Kumamoto147 Okayama133 Kashiwa-shi132 Niigata120 Fukushima114 Kagoshima107 Kanagawa105 Aichi104 Gifu103 Show all 938
All 938 locations
Target enrolment
to

Trials with a site in Osaka

354 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Eli Lilly and Company
Phase 3
3,000
Hamadayama, Suginami-ku, Himeji, Kisarazu, Kōriyama, Kumamoto, Kurume, Osaka, Shinjyuku
2026-12
Recruiting
Takeda
Phase 2
36
Nagoya, Kumamoto, Shinjuku-ku, Niigata, Osaka
2026-10-27
Recruiting
GlaxoSmithKline
Phase 3
720
Niigata, Osaka
2026-10-02
Recruiting
Kiminori Kimura, MD
Phase 2
7
Sapporo, Sendai, Osaka, Bunkyo-Ku
2026-10-01
Recruiting
GlaxoSmithKline
Phase 3
610
Fukuoka, Fukushima, Hokkaido, Ibaraki, Miyagi, Numakunai, Osaka, Saitama
2026-09-24
Recruiting
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
NCT07733180Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
DrugsLeucovorin·Adrucil·Tislelizumab·Oxaliplatin
BeOne Medicines
Phase 2
30
Yokohama, Takatsukishi, ChuoKu, Osaka
2026-09-14
Recruiting
GlaxoSmithKline
Phase 1/2
184
Osaka
2026-09-09
Recruiting
AbbVie
Phase 3
300
Osaka
2026-08-24
Recruiting
AstraZeneca
Phase 3
2,500
Chūōku, Fukuoka, Hachioji-shi, Osaka, Shibuya-ku, Takatsuki-shi
2026-08-19
Recruiting
Pfizer
Phase 3
375
Matsudo, Teine-ku, Nagaoka, Sakai, Shinagawa, Osaka
2026-08-17
Recruiting
AbbVie
Phase 2
168
Yokohama, Osaka, Chuo-Ku
2026-08-17
Recruiting
Eli Lilly and Company
Phase 2
606
Chūōku, Fukuoka, Iizuka, Osaka, Sendai, Ube
2026-08-07
Recruiting
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors
NCT07681882Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor
Daiichi Sankyo
Phase 1
45
Kashiwa, Osaka, Tokyo
2026-08-06
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
30
Osaka
2026-08-01
Recruiting
Pfizer
Phase 3
336
Kitakyushu-shi, Hamamatsu, Koto-ku, Mitaka, Shinjuku-ku, Niigata, Osaka
2026-07-30
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsASP2138·Folinic acid·Adrucil·Capecitabine
Astellas Pharma Global Development, Inc.
Phase 3
570
Kashiwa, Matsuyama, Sapporo, Akashi, Chuo-ku, Koto-ku, Niigata, Osaka
2026-07-28
Recruiting
GlaxoSmithKline
Phase 3
800
Ehime, Fukuoka, Gifu, Hokkaido, Kanagawa, Osaka, Tokyo, Toyama
2026-07-27
Recruiting
GlaxoSmithKline
Phase 4
28
Ehime, Fukui, Fukuoka, Gunma, Nagano, Osaka, Saitama, Shiga
2026-07-15
Recruiting
UCB BIOSCIENCES, Inc.
Phase 3
200
Chiyoda-ku, Kodaira, Kurume, Musashimurayama-shi, Osaka, Setagaya-ku
2026-07-14
Recruiting
Gilead Sciences
Phase 3
590
Osaka
2026-07-14
Recruiting
Eli Lilly and Company
Phase 3
170
Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai
2026-07-08
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Nagoya, Kita, Hirakata, Chūō, Kotoku, Osaka
2026-07-02
Recruiting
Kowa Company, Ltd.
Phase 4
120
Hokkaido, Ibaraki, Kagawa, Kanagawa, Osaka, Saitama, Tokyo
2026-07-01
Recruiting
ViiV Healthcare
Phase 3
564
Aichi, Kanagawa, Osaka, Tokyo
2026-06-25
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 3
784
Aichi, Fukuoka, Hokkaido, Kanagawa, Miyagi, Osaka, Tokyo, Toyama
2026-06-24
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
80
Kashiwa, Maebashi, Niigata, Hirakata, Osaka, Sakai, Hidaka, Sunto-gun
2026-06-19
Recruiting
Yonsei University
Not applicable
748
Osaka
2026-06-18
Recruiting
GlaxoSmithKline
Phase 3
450
Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama
2026-06-18
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
Yokohama, Kumamoto, Isahaya-shi, Urasoe, Osaka, Shinjuku-ku
2026-06-11
Recruiting
Asan Medical Center
Phase 4
1,058
Osaka
2026-06-05
Recruiting
Pfizer
Phase 3
3,230
Toyota-shi, Fukui-shi, Fukuoka, Kasuga, Sapporo, Hioki, Osaka, Bunkyo
2026-05-29
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Nagasaki, Osaka, Tokyo
2026-05-25
Recruiting
AbbVie
Phase 3
990
Kashiwa-shi, Matsuyama, Kobe, Kawasaki-shi, Osaka, Koto-ku
2026-05-22
Recruiting
Takeda
Phase 2
222
Fukuoka, Nagano, Izumisano, Osaka
2026-05-17
Recruiting
Novartis Pharmaceuticals
Observational
10
Kobe, Ushiku, Kanoya, Yokohama, Osaka
2026-05-13
Recruiting
Novo Nordisk A/S
Phase 3
300
Fukuoka, Hiroshima, Kumamoto, Okinawa, Osaka, Sapporo-shi, Hokkaido, Shizuoka, Tokyo
2026-05-05
Recruiting
Rohto Pharmaceutical Co., Ltd.
Phase 2
50
Osaka
2026-04-28
Recruiting
Alkermes, Inc.
Phase 3
176
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-ku, Kumamoto, Tokyo
2026-04-22
Recruiting
BioMarin Pharmaceutical
Phase 2/3
160
Hokkaido, Osaka, Tokyo
2026-04-20
Recruiting
Aesculap AG
Observational
178
Fukuoka, Okayama, Kyoto, Osaka-Fu, Osaka
2026-04-10
Recruiting
Incyte Corporation
Phase 3
588
Akashi, HYGO, Fukuoka Fukuoka, Kahoku-gun, Kitaadachi-gun, Kōtoku, Mitaka-shi, Osaka, Sapporo Hokkaido
2026-04-09
Recruiting
Alkermes, Inc.
Phase 3
150
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-Ku, Kumamoto
2026-04-06
Recruiting
TAMBE Japan Post-Marketing Surveillance
NCT07147569Thoracoabdominal Aortic Aneurysm, Pararenal Aortic Aneurysm
W.L.Gore & Associates
Observational
100
Minatoku, Nagoya, Osaka, Suita
2026-03-27
Recruiting
Bristol-Myers Squibb
Phase 3
325
Suita, Nankoku-shi, Osaka
2026-03-25
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
2026-03-23
Recruiting
Amgen
Phase 3
406
Tomakomai-shi, Osaka, Chuo-shi
2026-03-23
Recruiting
Novartis Pharmaceuticals
Observational
30
Kurume, Osaka, Suita, Bunkyo Ku
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Hirosaki, Kitakyushu, Fukushima, Osaka, Yamagata
2026-03-18
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Nagoya, Chiba, Kashiwa, Matsuyama, Yokohama, Kurashiki, Osaka, Suita
2026-03-13
Recruiting
Takeda
Phase 3
1,182
Minami-ku, Nagoya-shi, Nagoya, Fukuoka, Tsu, Mie, Sasebo-shi, Osaka, Chuo-ku, Meguro-Ku
2026-03-11
Active, closed
Ipsen
Phase 1
6
Kanagawa, Kobe, Kyoto, Osaka, Tokyo
2026-03-10
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Kashiwa, Koto-Ku, Chiba, Fukuoka, Kanagawa, Osaka, Tokyo, Wakayama
2026-03-09
Recruiting
ViiV Healthcare
Phase 2
186
Fukuoka, Kanagawa, Okinawa, Osaka, Tokyo
2026-02-11
Recruiting
Eli Lilly and Company
Phase 3
900
Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Fukuoka, Kitahiroshima, Kitakyushu, Minatoku, Osaka, Sapporo, Shibuya-ku
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
300
Ichikawa, Iruma, Moriyama, Osaka, Sendai, Shizuoka
2026-02-05
Recruiting
Rabin Medical Center
Phase 3
254
Izumi-Shi, Nara, Osaka, Setagaya-Ku
2026-02-01
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Fuchū, Kagoshima, Kitakyushu-shi, Osaka, Sanuki, Shimonoseki
2026-01-15
Recruiting
Takara Bio Inc.
Phase 3
5
Osaka, Fukuoka, Kashiwa
2026-01-05
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-12-19
Recruiting
TBE Zone 2 PMS in Japan
NCT07049913Aneurysm Thoracic, Dissection of Aorta, Thoracic, Trauma
W.L.Gore & Associates
Observational
200
Osaka
2025-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Kashiwa, Yokohama, Chūō, Koto, Osaka
2025-12-04
Recruiting
Takeda
Phase 3
110
Nagoya, Kitakyushu-shi, Tsu, Mie, Osaka, tabashi City
2025-12-04
Recruiting
AstraZeneca
Phase 3
1,100
Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi
2025-12-04
Recruiting
GlaxoSmithKline
Phase 3
450
Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Kumamoto, Miyagi, Osaka
2025-12-03
Recruiting
Amgen
Phase 3
750
Nagoya, Matsuyama, Fukuoka, Kobe, Kanazawa, Kita-gun, Sagamihara-shi, Osaka
2025-11-28
Recruiting
Genmab
Phase 3
660
Chiba, Ōta, Shiwa-gun, Sagamihara-shi, Yokohama, Tsu, Sendai, Osaka
2025-11-28
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-11-25
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Ichikawa, Kagoshima, Kanagawa, Nagoya, Osaka, Sakai, Sapporo
2025-11-24
Recruiting
Institut de Recherches Internationales Servier
Phase 1/2
20
Nagano, Osaka, Shizuoka
2025-11-24
Active, closed
Bayer
Phase 2
60
Nagoya, Chuo-Ku, Osaka
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
900
Osaka, Aichi, Chiba, Ehime, Fukuoka, Gifu, Hiroshima, Hokkaido
2025-11-18
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Hyōgo, Osaka
2025-11-18
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Hiroshima, Hyōgo, Kagawa, Kochi, Okayama, Osaka, Tokyo
2025-11-12
Recruiting
Eli Lilly and Company
Phase 2
252
Fukuoka, Kamakura, Kashiwa, Osaka, Sakura, Sapporo
2025-11-10
Recruiting
National Cancer Center, Japan
Phase 2
27
Fukuoka, Osaka, Tokyo
2025-11-04
Recruiting
Navitor Japan Study
NCT07193888Severe Aortic Stenosis
Abbott Medical Devices
Observational
100
Fukuoka, Kanagawa, Osaka
2025-10-30
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Nagoya, Kashiwa, Sapporo, Yokohama, Chuo-ku, Koto, Osaka
2025-10-23
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
Kashiwa, Kyoto, Osaka, Tokyo
2025-10-21
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
Chiyoda-ku, Osaka, Toyoake
2025-10-20
Recruiting
GlaxoSmithKline
Phase 1/2
47
Chiba, Osaka, Tokyo
2025-10-20
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Sapporo, Kobe, Osaka
2025-10-20
Recruiting
Genentech, Inc.
Phase 2
224
Kashiwa-shi, Fukuoka, Fukuyama-shi, Kanazawa, Takamatsu, Osaka, Saga, Fujidera-shi
2025-09-29
Recruiting
Sanofi
Phase 4
218
Ube, Kyoto, Osaka
2025-09-22
Recruiting
LUPKYNIS Drug-use Results Survey
NCT07053891Lupus Nephritis
DrugsVoclosporin·Lupkynis
Otsuka Pharmaceutical Co., Ltd.
Observational
400
Osaka
2025-09-17
Recruiting
Pfizer
Phase 3
140
Sendai, Niigata, Osaka, Hamamatsu, Mitaka
2025-09-10
Recruiting
CSL Behring
Phase 2
180
Chikushino-shi, Fukuoka, Ibaraki, Iizuka-shi, Kyoto, Mie, Osaka, Shimonoseki-shi
2025-09-03
Recruiting
AbbVie
Phase 2
140
Nagoya, Kashiwa-shi, Fukuoka, Gifu, Yokohama, Sendai, Osaka, Sunto-gun
2025-09-02
Recruiting
AbbVie
Observational
2,795
Ebina-shi, Osaka, Mitaka-shi, Ōta-ku
2025-09-02
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Aomori, Bunkyō City, Chūōku, Hiroshima, Izunokuni, Osaka, Saga, Shimotsuke
2025-08-22
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Kashiwa, Sunto-gun, Bunkyo-ku, Koto, Fukuoka, Osaka
2025-08-19
Recruiting
Takeda
Phase 3
150
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-08-14
Active, closed
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 2
20
Nagoya, Chuo Ku, Osaka
2025-08-08
Recruiting
AstraZeneca
Phase 2
278
Bunkyō City, Fukuyama-shi, Kobe, Kurume-shi, Kyoto, Osaka, Sakaishi, Shinjuku-ku
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Chiba, Kyoto, Osaka
2025-08-06
Active, closed
Pfizer
Phase 3
208
Sendai, Niigata, Hamamatsu, Mitaka, Osaka
2025-07-31
Recruiting
BioMarin Pharmaceutical
Phase 2
60
Kumamoto, Osaka, Tokyo, Tottori
2025-07-30
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Fukuoka, Chikusa, Nagaizumi-chō, Okayama, Osaka, Sakai, Tokyo, Wakayama
2025-07-17
Recruiting
AstraZeneca
Phase 2
100
Chūōku, Fukuoka, Hidaka-shi, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osaka
2025-07-17
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Sapporo, Yokohama, Bunkyo-ku, Shinjuku-ku, Chiba, Fukuoka, Okayama, Osaka
2025-07-14
Recruiting
Novo Nordisk A/S
Phase 2
200
Bunkyo-ku, Tokyo, Hamamatsu-shi, Shizuoka, Himeji-shi, Hyogo, Ibaraki, Kanagawa, Kita-gun, Kagawa, Kobe-shi, Hyogo, Osaka
2025-06-30
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
Aomori, Osaka, Tokyo
2025-06-26
Recruiting
Yukinori Ozaki
Phase 2
24
Nagoya, Kashiwa-shi, Gifu, Hiroshima, Sapporo, Akashi-shi, Okayama, Osaka
2025-06-24
By invitation
BioMarin Pharmaceutical
Phase 3
140
Osaka, Tokushima, Tokyo, Tottori
2025-06-20
Active, closed
AbbVie
Phase 3
125
Nagoya, Kurume-shi, Kahoku-gun, Ebina-shi, Miyagi-gun, Sendai, Niigata, Osaka
2025-06-19
Recruiting
GlaxoSmithKline
Phase 1/2
346
Aichi, Chiba, Hokkaido, Osaka, Tokyo
2025-06-11
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
Osaka, Sendai, Tokyo
2025-06-10
Active, closed
Stoke Therapeutics, Inc
Phase 3
170
Fukuoka, Hokkaido, Kyoto, Nagoya, Niigata, Okayama, Osaka, Shimotsuke
2025-06-04
Recruiting
Aveir Leadless Pacemaker Japan PMS
NCT07106788Leadless Pacemaker
Abbott Medical Devices
Observational
304
Nagoya, Kitakyushu, Kawasaki, Sendai, Kurashiki, Hirakata, Osaka, Suita
2025-05-26
Active, closed
Upstream Bio Inc.
Phase 2
396
Tokyo, Hokkaido, Osaka, Ibaraki
2025-05-21
Recruiting
Joseph Broderick, MD
Phase 3
350
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Niigata, Osaka
2025-05-06
Recruiting
Otsuka Pharmaceutical Co., Ltd.
Observational
200
Osaka
2025-04-17
Active, closed
Bayer
Observational
3,000
Osaka
2025-04-14
By invitation
Stella Pharma Corporation
Phase 1/2
30
Osaka
2025-04-10
Recruiting
Pfizer
Phase 3
674
Kurume, Sendai, Niigata, Hamamatsu, Koto-ku, Mitaka, Shinjuku-ku, Osaka
2025-04-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Kashiwa, Koto, Osaka
2025-03-25
Recruiting
Takeda
Phase 3
171
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-02-27
Active, closed
Amgen
Phase 2
252
Kurume-shi, Sapporo, Yokohama, Niigata, Hirakata-shi, Osaka, Sunto-gun, Koto-ku
2025-02-26
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Fukuoka, Kita Gun, Nagoya, Osaka, Ōita, Sasebo, Sendai, tabashi City
2025-02-21
Recruiting
GlaxoSmithKline
Phase 2
120
Osaka, Tokyo
2025-02-18
Recruiting
AbbVie
Phase 3
420
Kobe, Kochi, Osaka, Shibuya-ku, Shinjuku-ku, Tendo-shi, Kai, Kagoshima
2025-02-13
By invitation
Longboard Pharmaceuticals
Phase 3
324
Narita-shi, Okayama, Osaka, Saitama-shi, Mibu-Machi, Kodaira-shi, Niigata, Shizuoka
2025-02-12
Active, closed
AbbVie
Phase 3
468
Kobe, Kawasaki-shi, Kochi, Sendai, Ōita, Osaka, Setagaya-ku, Shibuya-ku
2025-02-10
Recruiting
RCT of EFTR Versus STER for GIST Treatment
NCT07411118Small Size Gastrointestinal Stromal Tumors, GIST
Chinese University of Hong Kong
Not applicable
136
Osaka
2025-02-01
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo
2025-02-01
Active, closed
Janssen Research & Development, LLC
Phase 3
813
Chiba, Chūōku, Hirakata, Hyōgo, Kitakyushu-shi, Nagoya, Osaka, Ōita
2025-01-09
Active, closed
Daiichi Sankyo
Phase 2
335
Akashi, Chūōku, Fukuoka, Hidaka, Kashiwa, Kōtoku, Nagoya, Osaka
2025-01-06
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Kashiwa-shi, Kōtō City, Osaka, Tokyo, Toyama, Ube, Yokohama
2024-12-13
Active, closed
Boston Scientific Corporation
Not applicable
186
Amagasaki, Yokohama, Kishiwada, Osaka, Kawagoe, Shizuoka, Minato, Wakayama
2024-12-13
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Chiba, Chūōku, Kashiwa, Nagoya, Osaka, Sakai, Shizuoka, Suita
2024-12-12
Active, closed
Kyowa Kirin Co., Ltd.
Phase 3
13
Ōbu, Suita, Waizumi, Fuchū, Yonago, Niigata, Okayama, Osaka
2024-12-01
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama
2024-11-27
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
23
Nagoya, Sapporo, Kobe, Osaka, Chuo-ku, Chiba, Fukuoka, Fukushima
2024-11-25
Recruiting
Eli Lilly and Company
Phase 3
125
Iruma-Gun, Isesaki-shi, Kyoto, Meguro-Ku, Moriyama, Nara, Osaka, Saga
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
150
Iruma-Gun, Isesaki-shi, Kawaramachidori, Kamigyo-ku, Kyoto-city, Meguro-Ku, Moriyama, Nara, Osaka, Saga
2024-11-18
Active, closed
Pfizer
Phase 3
636
Kobe, Nishinomiya, Osaka, Shibuya-ku, Kai, Kagoshima
2024-11-15
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Narita-shi, Fukuoka, Sapporo, Okayama, Osaka, Saitama-shi, Mibu-Machi, Kodaira-shi
2024-11-11
Active, closed
GlaxoSmithKline
Phase 2
283
Chiba, Hokkaido, Hyōgo, Kagawa, Kumamoto, Osaka, Tokyo, Yamanashi
2024-11-11
Recruiting
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc
Observational
140
Osaka, Toyoake
2024-11-04
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 3
6
Osaka, Tokyo
2024-10-25
Active, closed
Eli Lilly and Company
Phase 2
45
Nagoya, Osaka, Setagaya-Ku Tokyo
2024-10-25
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Chiba, Chūōku, Kashiwa, Nagoya, Osaka, Shizuoka, Suita, Tokyo
2024-10-18
Active, closed
J-Valve Transfemoral Pivotal Study
NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
194
Tokyo, Osaka
2024-10-17
Active, closed
Revolution Medicines, Inc.
Phase 3
500
Chiba, Nagoya, Osaka, Tokyo, Yokohama
2024-10-16
Active, closed
Ipsen
Phase 2
670
Fukuoka, Hiroshima, Hyōgo, Kagoshima, Kyoto, Miyagi, Osaka, Shizuoka
2024-10-10
Active, closed
Gilead Sciences
Phase 3
609
Chiba, Nagoya, Okinawa, Osaka, Osaka Fu, Tokyo
2024-10-09
Active, closed
Gilead Sciences
Phase 3
600
Chiba, Nagoya, Okinawa, Osaka, Osaka Fu, Tokyo
2024-10-08
Active, closed
Eisai Inc.
Phase 2
105
Ōbu, Ōtake, Honjō, Kurashiki, Shinjuku, Osaka, Yamagata
2024-09-30
Recruiting
GlaxoSmithKline
Phase 2
393
Chiba, Ehime, Gunma, Hokkaido, Kagawa, Nara, Niigata, Osaka
2024-09-27
Active, closed
Longboard Pharmaceuticals
Phase 3
108
Narita-shi, Fukuoka, Sapporo, Okayama, Osaka, Saitama-shi, Mibu-Machi, Kodaira-shi
2024-09-25
Active, closed
Hoffmann-La Roche
Phase 3
338
Fukuoka, Miyagi, Osaka, Tokyo, Wakayama
2024-09-23
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Chiba, Kanagawa, Nagoya, Osaka, Tokyo
2024-09-12
Active, closed
Takeda
Phase 3
2,099
Nagoya, Fukutsu-shi, Obihiro-Shi, Sapporo, Fukuoka, Osaka, Kusatsu-shi, Shimotsuke-shi
2024-09-04
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Koto-Ku, Chou-ku, Osaka
2024-08-31
Active, closed
Kite, A Gilead Company
Phase 3
452
Hyōgo, Nagoya, Osaka, Tochigi, Tokyo
2024-08-23
Recruiting
Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity.
NCT06629636Repeated IVF Failure, Female Infertility
Sunkaky Medical Cooperation
Not applicable
60
Osaka
2024-08-20
Recruiting
Colorado Prevention Center
Phase 3
2,600
Sapporo, Isehara, Sagamihara, Kyoto, Sendai, Osaka, Suita, Ōta-ku
2024-08-20
Active, closed
TAV-in-SAV in Japanese Patients
NCT06826027Valve-in-valve Procedures
Osaka University
Observational
180
Urayasu, Fukuoka, Kurume, Okayama, Osaka, Suita, Saga, Koshigaya
2024-08-07
Active, closed
Pfizer
Observational
450
Kitakyushu-shi, Kurume-shi, Ebina, Sendai, Niigata, Osaka, Hamamatsu, Bunkyo-ku
2024-08-07
By invitation
Federal University of São Paulo
Observational
4,500
Osaka, Tokyo
2024-08-01
Recruiting
NovoCure GmbH
Phase 3
734
Osaka, Sakai, Hidaka, Bunkyo, Chuo-ku
2024-07-31
Active, closed
AstraZeneca
Observational
40
Chiba, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Mie, Okayama, Osaka
2024-07-16
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Fukuoka, Asahikawa, Kita-gun, Sagamihara, Yokohama, Nagano, Kawachi-Nagano, Osaka
2024-06-28
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Aichi, Nagoya, Isehara, Kagoshima, Kanagawa, Yokohama, Kashiwa-shi, Kyoto, Osaka, Tokyo, Koto-ku
2024-06-28
Active, closed
AbbVie
Phase 3
1,400
Nagoya, Toyoake, Obihiro-Shi, Shiwa-gun, Kyoto, Niigata, Ginowan-shi, Osaka
2024-06-27
Active, closed
BioMarin Pharmaceutical
Phase 3
80
Osaka, Tokushima, Tokyo, Tottori
2024-06-17
Recruiting
ABX advanced biochemical compounds GmbH
Phase 3
434
Osaka, Tokyo
2024-06-13
Active, closed
GlaxoSmithKline
Phase 4
302
Fukuoka, Miyagi, Osaka, Tokyo
2024-06-06
Recruiting
Polyethylene Wear Particle Analysis of THA
NCT06432543Wear of Articular Bearing Surface of Prosthetic Joint, Hip Arthropathy
Osaka Metropolitan University
Observational
90
Osaka
2024-06-01
Active, closed
Cytokinetics
Phase 2/3
65
Kagoshima, Osaka, Sagamihara, Suita, Tokyo
2024-05-29
Active, closed
GlaxoSmithKline
Phase 2
41
Aichi, Fukuoka, Gunma, Hokkaido, Hyōgo, Numakunai, Okayama, Osaka
2024-05-07
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
31
Kashiwa-shi, Sendai, Niigata, Osaka, Osakasayama-shi, Sunto-gun, Chuo-ku, Koto-ku
2024-05-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Nagoya, Kashiwa, Nankoku, Kitaadachi-gun, Chūō, Koto, Fukuoka, Osaka
2024-05-03
Recruiting
AstraZeneca
Phase 3
582
Chūōku, Fukuoka, Kashiwa, Kōtoku, Niigata, Osaka, Sakai, Sapporo
2024-04-29
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Amagasaki, Kawasaki, Kobe, Kumamoto, Osaka, Ōta-ku, Saitama, Wakayama
2024-04-18
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Chiba, Morioka, Sagamihara-shi, Kyoto, Sendai, Moriguchi-shi, Osaka, Kawagoe-shi
2024-04-16
Active, closed
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
260
Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kyoto, Nagoya, Osaka, Tochigi
2024-03-27
Active, closed
Gilead Sciences
Phase 3
577
Aichi, Osaka, Tokyo
2024-03-25
Active, closed
Bristol-Myers Squibb
Phase 2
310
Nagoya, Toride-Shi, Kurashiki-Shi, Hirakata-Shi, Osaka, Bunkyo-Ku, Hachioji-Shi, Setagaya-Ku
2024-03-20
Recruiting
Verastem, Inc.
Phase 3
270
Tsu, Aichi, Miyagi, Osaka, Tokyo
2024-03-18
Active, closed
AstraZeneca
Phase 3
594
Fukuoka, Kashiwa, Kōtoku, Nagoya, Ogaki-shi, Osaka, Sunto-gun, Tokyo
2024-03-04
Active, closed
Daiichi Sankyo
Phase 1
210
Chūōku, Fukuoka, Kashiwa, Kōtoku, Nagoya, Osaka, Ōsaka-sayama, Shizuoka
2024-02-22
Active, closed
ViiV Healthcare
Phase 3
463
Aichi, Osaka, Tokyo
2024-02-21
Active, closed
Janssen Pharmaceutical K.K.
Phase 3
19
Hokkaido, Ichinomiya, Kitakyushu-shi, Kumamoto, Nagoya, Osaka, Sendai, Shimotsuga Gun
2024-02-09
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Ehime, Kyoto, Okayama, Osaka, Sapporo, Tochigi, Tokyo, Yamagata
2024-02-05
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
Tōon, Nishinomiya, Kashiwa, Osaka
2024-02-01
Active, closed
Pfizer
Phase 2
333
Otashi, Sendai, Suita, Chuo-ku, Chiba, Hiroshima, Osaka
2024-01-09
Recruiting
Tampere University Hospital
Observational
3,000
Osaka
2024-01-08
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Hiroshima, Iizuka-shi, Osaka, Sapporo, Yaizu-shi
2024-01-03
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka
2023-12-29
Recruiting
Intellia Therapeutics
Phase 3
1,200
Kumamoto, Osaka, Tokyo, Toyama
2023-12-13
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
87
Nagoya, Kashiwa-shi, Kanazawa, Yokohama, Osaka, Hamamatsu, Bunkyo-ku, Koto-Ku
2023-12-06
Active, closed
Polyethylene Wear Particle Analysis of TKA
NCT06426641Wear of Articular Bearing Surface of Prosthetic Joint, Total Knee Arthroplasty
Osaka Metropolitan University
Observational
90
Osaka
2023-12-05
Active, closed
AstraZeneca
Phase 3
760
Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Mitaka-shi, Nagoya, Osaka, Sendai
2023-12-04
Active, closed
GlaxoSmithKline
Phase 2
316
Aichi, Chiba, Hyōgo, Osaka, Saitama, Shizuoka, Tokyo
2023-11-14
Active, closed
AbbVie
Phase 3
122
Kashiwa-shi, Kurume-shi, Sapporo, Sendai, Izumi-Shi, Osaka, Saitama-shi, Bunkyo-ku
2023-11-06
Recruiting
Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients
NCT06014801Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
Jikei University School of Medicine
Phase 2/3
400
Sendai, Takatsuki, Fukui, Ibaraki, Osaka, Tochigi, Tokyo, Wakayama
2023-10-30
Recruiting
AbbVie
Phase 3
1,500
Kurume-shi, Sagamihara-shi, Niigata, Osaka, Hamamatsu, Mitaka-shi, Shinjuku-ku, Ube-shi
2023-10-11
Active, closed
Servier
Phase 2
12
Kashiwa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo, Yokohama
2023-10-10
Active, closed
Stichting European Myeloma Network
Phase 3
759
Bunkyō City, Fukuoka, Hokkaido, Hyōgo, Kanazawa, Nagoya, Okayama, Osaka
2023-10-10
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Toyoake, Fuchū, Hachiōji, Okayama, Osaka
2023-10-02
Recruiting
Kyoto University Hospital
Phase 2
30
Kobe, Tsukuba, Kyoto, Osaka
2023-10-01
Active, closed
Incyte Corporation
Phase 1
160
Chiba-ken, Kagoshima, Osaka, Tokyo, Tsu
2023-09-25
Active, closed
Pfizer
Phase 2
507
Yokohama, Osaka, Chuo-ku, Setagaya-ku
2023-08-22
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Chūōku, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Osaka, Ōsaka-sayama, Sapporo
2023-08-18
Active, closed
AstraZeneca
Phase 3
142
Chūōku, Kanazawa, Kashiwa, Kyoto, Osaka, Sendai, Ube, Wakayama
2023-08-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Sapporo, Nankoku, Sakai, Izumo, Koto, Hiroshima, Nagasaki, Osaka
2023-08-08
Active, closed
Incyte Corporation
Phase 2
247
Chūōku, Fukuoka, Kishiwada, Kitakyushu-shi, Mizunami-shi, Osaka, Sakaide-shi, Sapporo
2023-07-11
Active, closed
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498Percutaneous Coronary Intervention
CathWorks Ltd.
Not applicable
1,924
Fukuyama, Gifu, Ichinomiya, Kobe, Matsudo, Osaka, Tokyo
2023-06-21
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Chiba, Osaka, Tokyo, Wakayama
2023-06-20
Recruiting
GlaxoSmithKline
Phase 1/2
123
Aomori, Chiba, Kanagawa, Osaka, Tokyo, Yamagata
2023-06-14
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Chiba, Kanazawa, Osaka, Tokushima, Tottori
2023-06-07
By invitation
AbbVie
Phase 3
650
Kobe, Nishinomiya-shi, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-06-05
Recruiting
Daiichi Sankyo
Phase 1
128
Gifu, Nakatogari, Osaka, Tokyo
2023-05-30
Recruiting
Osaka University
Phase 2
45
Osaka
2023-05-25
Recruiting
Chugai Pharmaceutical
Phase 1
209
Nagoya, Kashiwa-shi, Yokohama, Hirakata-shi, Osaka, Sakai-shi, Nagaizumi-chō, Chuo-ku
2023-05-24
Active, closed
Servier Affaires Médicales
Phase 3
299
Kanagawa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo
2023-05-03
Recruiting
AbbVie
Phase 3
450
Kobe, Nishinomiya, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-05-01
Active, closed
TrEatment Approach in the Multimodal Era Registry
NCT05629052Chronic Thromboembolic Pulmonary Hypertension, CTEPH
International CTEPH Association
Observational
1,000
Okayama, Osaka
2023-04-12
Recruiting
Takeda
Phase 2/3
500
Kurume-Shi, Kumamoto, Nagasaki, Osaka, Bunkyo-Ku, Nagakute
2023-04-05
Active, closed
GlaxoSmithKline
Phase 2
154
Chiba, Kanagawa, Osaka
2023-04-03
Active, closed
Multi-omics Study in Citrin Deficiency
NCT06895746Citrin Deficiency
Johannes Haeberle
Observational
100
Kurume-shi, Saitama, Yokohama, Tokyo, Sendai, Matsumoto, Hokkaido, Osaka
2023-04-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
641
Nagoya, Bunkyo, Shinjuku-ku, Shinjyuku-ku, Osaka
2023-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
537
Nagoya, Shinjuku-ku, Shinjyuku-ku, Osaka
2023-03-08
Active, closed
Otsuka Pharmaceutical Co., Ltd.
Observational
1,600
Osaka
2023-03-03
Recruiting
Eli Lilly and Company
Phase 3
595
Hamamatsu, Kurume, Mitaka, Miyagi-gun, Niigata, Osaka, Shinjuku-ku, Ube
2023-02-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
514
Nagoya, Shinjyuku-ku, Osaka
2023-02-17
Active, closed
Kite, A Gilead Company
Phase 3
300
Kyoto, Miyagi, Osaka, Tokyo
2023-02-10
Active, closed
TRISCEND JAPAN Study
NCT05760989Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Not applicable
53
Kitakyushu-shi, Isehara-shi, Sendai, Osaka, Suita, Suita-shi, Shinjuku-Ku
2023-02-06
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Nagoya, Osaka, Suita, Kofu, Kumamoto
2023-02-02
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Chūō, Fukuoka, Kyoto, Osaka, Sapporo, Tokyo
2023-01-23
Active, closed
Zenas BioPharma (USA), LLC
Phase 3
194
Kitakyushu, Kokura, Kanazawa, Hiragi, Matsumoto, Osaka, Bunkyō-Ku, Minato-ku
2023-01-09
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Nagoya, Asahikawa, Chuo Ku, Hamamatsu, Shinjuku-Ku, Osaka
2023-01-05
By invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 2/3
150
Hiroshima, Kanagawa, Osaka, Tokyo
2022-12-28
Active, closed
Bristol-Myers Squibb
Phase 2/3
230
Kitakyushu-shi, Sapporo, Amagasaki, Sagamihara, Sendai, Shinagawa-ku, Osaka
2022-12-14
By invitation
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Kurume-Shi, Fukuoka, Hamamatsu, Kumamoto, Kurume, Matsumoto, Okayama, Osaka
2022-11-30
Active, closed
Sanofi
Phase 2
187
Nagaoka, Hamamatsu, Chūō, Fukushima, Osaka, Ōita, Saitama
2022-11-25
Active, closed
Hoffmann-La Roche
Phase 3
68
Fukuoka, Hyōgo, Kagoshima, Kumamoto, Osaka, Tokyo
2022-11-01
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Sapporo, Suita-shi, Aichi, Chiba-shi, Chiba, Gunma, Kanagawa, Osaka, Saitama
2022-11-01
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
80
Bunkyō City, Kyoto, Osaka, Shibuya-ku, Tsukuba
2022-10-28
Active, closed
GlaxoSmithKline
Phase 2
351
Chiba, Fukuoka, Hyōgo, Kanagawa, Osaka, Saitama
2022-10-14
Active, closed
Eli Lilly and Company
Phase 3
15,374
Chūōku, Fukuoka, Izumisano, Kyoto, Minatoku, Onga-gun, Osaka, Uji
2022-10-11
Active, closed
Genmab
Phase 1
17
Nagoya, Kyoto, Osaka, Chuo-ku, Setagaya-ku
2022-10-04
Active, closed
PedAL BCU, LLC
Phase 3
120
Nagoya, Kobe, Saitama-Shi, Setagaya-Ku, Osaka
2022-10-01
Active, closed
Kite, A Gilead Company
Phase 3
231
Hyōgo, Kyoto, Miyagi, Okayama, Osaka
2022-09-22
Recruiting
Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
NCT05325034Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis, Hypercholesterolemia
Stephen Nicholls
Not applicable
2,000
Fukuoka, Mitaka, Osaka
2022-09-15
Active, closed
Hoffmann-La Roche
Phase 3
139
Chiba, Fukuoka, Fukushima, Hyōgo, Kanagawa, Miyagi, Osaka, Tokyo
2022-08-30
Active, closed
Biogen
Phase 2
416
Toon-shi, Himeji-shi, Kawasaki-shi, Yokohama, Osaka, Suita-shi, tabashi City
2022-08-24
Active, closed
Gilead Sciences
Phase 2/3
689
Nagoya, Osaka, Tokyo
2022-08-16
Active, closed
Novo Nordisk A/S
Phase 3
412
Fukuoka-shi, Fukuoka, Kobe-shi, Hyogo, Kyoto, Nara-shi, Nara, Niigata-shi, Niigata, Okayama-shi, Okayama, Osaka, Saitama-shi, Saitama
2022-08-10
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Osaka, Bunkyo Ku, Koto Ku
2022-07-07
Active, closed
Sanofi
Phase 3
531
Nagoya, Kamogawa, Higashiibaraki, Yahaba, Kamakura, Okayama, Kyoto, Osaka
2022-06-23
Recruiting
Priothera SAS
Phase 3
366
Anjo-shi, Nagoya, Kanazawa, Osaka, Shimotsuke-shi, Fukuoka, Hiroshima, Kobe
2022-06-16
Recruiting
Nuvalent Inc.
Phase 1/2
840
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
2022-06-09
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Kashiwa-shi, Sapporo, Suita-shi, Tokushima, Koto-ku, Osaka
2022-05-03
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
Kanagawa, Isehara, Kawasaki, Osaka
2022-04-27
Active, closed
Hoffmann-La Roche
Phase 3
208
Fukuoka, Hokkaido, Miyagi, Osaka, Tokyo, Yamagata
2022-04-25
Recruiting
Otsuka Pharmaceutical Co., Ltd.
Observational
1,000
Osaka
2022-04-20
Active, closed
Janssen Research & Development, LLC
Phase 1/2
235
Fukuoka, Kofu, Osaka, Toyama
2022-04-11
Active, closed
Daiichi Sankyo
Phase 2
187
Chūōku, Kashiwa, Kōtoku, Nagaizumi-chō, Osaka, Ōsaka-sayama, Yokohama
2022-03-09
Recruiting
Pfizer
Phase 3
160
Fuchū, Osaka
2022-03-07
Active, closed
AstraZeneca
Phase 3
390
Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka
2022-02-21
Active, closed
AstraZeneca
Phase 3
1,051
Himeji-shi, Hiroshima, Kashiwa, Kurume-shi, Natori-shi, Niigata, Osaka, Sendai
2022-02-07
Active, closed
ADH1 and ADH2 Disease Monitoring Study (DMS)
NCT05227287Autosomal Dominant Hypocalcemia
Calcilytix Therapeutics, Inc., a BridgeBio company
Observational
95
Osaka, Tokyo
2022-01-20
Recruiting
Nuvalent Inc.
Phase 1/2
359
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
2022-01-04
Active, closed
Novartis Pharmaceuticals
Phase 1/2
46
Yokohama, Shinjuku-ku, Osaka
2021-12-27
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bunkyō City, Hiroshima, Kashiwa, Nagoya, Osaka, Osaka Sayama Shi, Sendai, Shimotsuke
2021-12-10
Active, closed
Taiho Pharmaceutical Co., Ltd.
Phase 1
78
Chiba, Hokkaido, Kumamoto, Osaka, Tokyo
2021-12-01
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Gunma, Hyōgo, Kanagawa, Kobe, Kurume, Nagoya, Niigata, Osaka
2021-11-17
Active, closed
AstraZeneca
Phase 3
454
Chūōku, Fukuoka, Kashiwa, Matsuyama, Niigata, Okayama, Osaka, Sakai
2021-10-28
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Ōmura, Ehime, Hokkaido, Osaka, Tokyo
2021-09-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
2,000
Nagoya, Shinjuku-ku, Shinjyuku-ku, Osaka, Tokyo
2021-09-15
Active, closed
Nuvation Bio Inc.
Phase 2
217
Fukuoka, Kashiwa, Miyagi, Nagoya, Osaka, Shizuoka, Tokyo
2021-09-01
Active, closed
Pfizer
Phase 3
38,861
Fukuoka, Itoshima, Amagasaki, Yokohama, Osaka, Kawaguchi, Chuo-ku, Hachioji-shi
2021-08-31
Active, closed
Eli Lilly and Company
Phase 3
2,996
Bunkyō City, Chūōku, Hachiōji, Osaka, Ōbu, Shinjuku, Shinjuku-ku, Suita-shi
2021-08-27
Active, closed
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Hyōgo, Meguro-ku, Osaka, Sapporo, Tokyo
2021-08-25
Active, closed
HUYABIO International, LLC.
Phase 3
450
Fukuoka, Matsumoto, Niigata, Okayama, Chuo Ku, Osaka, Nagaizumi-cho, Kōtoku
2021-08-12
Active, closed
VectivBio AG
Phase 3
158
Kanagawa, Osaka, Sendai, Tokyo
2021-07-13
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
434
Hokkaido, Kobe, Kumamoto, Kyoto, Nagasaki, Osaka, Saitama, Toyoake
2021-07-06
Recruiting
AB122 Platform Study
NCT04999761Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
DrugsPimitespib·Futibatinib·Domvanalimab·Ramucirumab
Taiho Pharmaceutical Co., Ltd.
Phase 1
917
Aichi, Chiba, Ehime, Hokkaido, Kanagawa, Osaka, Shizuoka, Tokyo
2021-06-01
Active, closed
Hoffmann-La Roche
Phase 3
557
Aichi, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Osaka, Tochigi
2021-04-26
Active, closed
Otsuka Pharmaceutical Co., Ltd.
Observational
300
Osaka
2021-03-29
Recruiting
Boston Scientific Corporation
Observational
5,000
Sapporo, Kyoto, Miyazaki, Aichi, Chiba, Osaka
2021-03-29
Recruiting
Bristol-Myers Squibb
Phase 3
153
Nagoya, Fukuoka, Jonan-Ku, Isehara, Tsu, Shinjuku-ku, tabashi City, Osaka
2021-03-23
Active, closed
Hoffmann-La Roche
Phase 3
342
Aichi, Chiba, Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo
2021-03-12
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Nagoya, Kashiwa, Osaka, Chuo Ku, Koto Ku
2021-02-24
Active, closed
Hoffmann-La Roche
Phase 2
920
Osaka, Tokyo
2021-01-18
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
40
Kashiwa-shi, Kobe, Yokohama, Ina, Osaka, Takatsuki-shi, Hidaka-shi, Koto-Ku
2021-01-13
Active, closed
Novartis Pharmaceuticals
Phase 2
24
Nagoya, Kashiwa, Isehara, Yokohama, Kumamoto, Sendai, Osaka, Suita
2021-01-08
Active, closed
Pfizer
Phase 3
841
Chiba, Kashiwa, Sapporo, Kanazawa, Kawasaki, Yokohama, Nagoya, Osaka
2020-12-21
Active, closed
Janssen Research & Development, LLC
Phase 2
220
Iizuka, Kanagawa, Kashihara-shi, Kisarazu-shi, Nagasaki, Osaka, Tokyo, Toyama
2020-12-18
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1/2
244
Kashiwa-shi, Sendai, Okayama, Hirakata-shi, Osaka, Shizuoka, Chuo-ku, Koto-ku
2020-12-16
Active, closed
Janssen Research & Development, LLC
Phase 1/2
228
Kanazawa, Nagoya, Osaka, Sendai, Shibuya City
2020-12-15
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Fukuoka, Kanazawa, Kashihara, Kawasaki, Niigata, Okayama, Osaka, Saitama
2020-12-11
Active, closed
GlaxoSmithKline
Phase 2/3
758
Kyoto, Miyagi, Osaka, Yamaguchi
2020-12-08
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Iizuka, Kanagawa, Kashihara, Kawagoe-Shi, Kisarazu-shi, Nagasaki, Osaka, Shūnan
2020-12-07
Active, closed
Amgen
Phase 3
135
Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kyoto, Niigata, Osaka, Tokyo
2020-12-04
Active, closed
Eli Lilly and Company
Phase 3
312
Kagoshima, Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Shinjuku-ku, Tokyo
2020-11-25
Active, closed
AbbVie
Phase 1
21
Fukuoka, Sapporo, Osaka, Chuo-shi
2020-11-11
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 1
59
Bunkyō City, Fukushima, Iruma, Kyoto, Nagasaki, Osaka, Sakai, Shinagawa-Ku
2020-10-30
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Nagoya, Kashiwa-shi, Kawasaki, Osaka, Chuo-ku, Koto-ku
2020-09-15
Active, closed
AstraZeneca
Phase 3
134
Chiba, Hamamatsu, Ichikawa-shi, Kawasaki-shi, Nishinomiya-shi, Osaka, Sendai
2020-07-20
Active, closed
Eisai Inc.
Phase 3
1,400
Obu-shi, Fukuoka, Kobe, Kamakura-shi, Kyoto, Sendai, Osaka, Suita-shi
2020-07-14
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 2
25
Nagoya, Sagamihara, Sendai, Hidaka, Hiroshima, Kumamoto, Kyoto, Osaka
2020-07-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Kurume, Kobe, Yokohama, Hirakata, Takatsuki, Fukuoka, Niigata, Osaka
2020-07-06
Recruiting
EORTC Metastatic Breast Cancer Module Development
NCT07806266Metastatic Beast Cancer
University of Leeds
Observational
568
Osaka, Tokyo
2020-05-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,033
Hachiōji, Fukuoka, Kumamoto, Osaka, Tokyo
2020-02-27
Active, closed
Amicus Therapeutics
Phase 3
21
Osaka, Gunma, Miyagi, Tokyo
2020-02-13
Active, closed
Pfizer
Phase 3
1,068
Matsuyama, Tōon, Fukuoka, Ōta, Sapporo, Yokohama, Osaka, Sakai
2019-12-30
Active, closed
Gilead Sciences
Phase 2/3
72
Nagoya, Osaka, Tokyo
2019-11-21
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Aichi, Hiroshima, Hyōgo, Niigata, Osaka, Saitama, Shizuoka, Tokyo
2019-11-13
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Osaka, Setagaya-ku
2019-11-04
Active, closed
Daiichi Sankyo
Phase 1/2
247
Aichi, Chiba, Hokkaido, Hyōgo, Kagawa, Osaka, Ōsaka-sayama, Saitama
2019-11-03
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
Chiba, Niigata, Osaka, Shizuoka, Tokyo
2019-10-31
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Ehime, Fukuoka, Kanagawa, Niigata, Osaka, Sapporo, Shizuoka, Tokyo
2019-07-15
Active, closed
Novo Nordisk A/S
Phase 2
62
Fukuoka, Fukuoka-shi, Fukuoka, Fukuyama-shi, Hiroshima, Kobe-shi, Hyogo, Kyoto, Nara-shi, Nara, Niigata-shi, Niigata, Osaka
2019-07-04
Active, closed
National Cancer Center Hospital East
Phase 2
51
Nagoya, Kashiwa, Hokkaido, Akashi, Kobe, Yokohama, Sendai, Osaka
2019-07-02
Active, closed
AstraZeneca
Phase 2
247
Chūōku, Fukuoka, Kōtoku, Nagoya, Osaka, Wakayama
2019-06-25
Active, closed
BioMarin Pharmaceutical
Phase 2
73
Osaka, Saitama, Tokushima
2019-06-12
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Sapporo, Nagaizumi-Cho, Chuo-ku, Niigata, Osaka
2019-06-04
Recruiting
Insel Gruppe AG, University Hospital Bern
Not applicable
104
Ageo, Gifu, Nagano, Osaka, Saitama, Sapporo
2019-05-28
Active, closed
AstraZeneca
Phase 3
810
Chūōku, Kashiwa, Kitaadachi-gun, Mitaka-shi, Osaka, Suita-shi, Wakayama, Yokohama
2019-04-16
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Chūōku, Habikino-shi, Kōtoku, Kurume-shi, Osaka, Sendai, Suita-shi
2019-03-22
Active, closed
Novartis Pharmaceuticals
Phase 2
22
Osaka
2019-03-13
Active, closed
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
NCT03833700Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
DrugE7386
Eisai Co., Ltd.
Phase 1
70
Nagoya, Kashiwa, Sapporo, Sendai, Nagaizumi-cho, Chuo Ku, Fukuoka, Osaka
2019-03-05
Recruiting
Cardiac Sarcoidosis Randomized Trial
NCT03593759Cardiac Sarcoidosis, Sarcoidosis
DrugsPrednisolone·Methotrexate·Prednisone
Ottawa Heart Institute Research Corporation
Phase 3
160
Sapporo, Chiba, Fukui, Kawasaki, Nagoya, Osaka, Tokyo
2019-01-15
Active, closed
AstraZeneca
Phase 3
216
Hiroshima, Kanazawa, Kashiwa, Nagoya, Niigata, Osaka, Sakaishi, Sapporo
2018-07-19
Active, closed
Kyowa Kirin Co., Ltd.
Observational
226
Osaka
2018-05-01
Active, closed
Bristol-Myers Squibb
Phase 3
545
Kashiwa-shi, Kurume-shi, Sapporo, Nishinomiya-shi, Morioka, Kumamoto, Osaka, Ōsaka-sayama
2018-04-18
Active, closed
Eli Lilly and Company
Phase 3
533
Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Sendai, Shinjuku-ku, Tokyo
2018-03-14
Active, closed
BioMarin Pharmaceutical
Phase 3
119
Osaka, Saitama, Tokushima
2017-12-12
Active, closed
Daiichi Sankyo
Phase 1
312
Kashiwa-Shi, Kurume-Shi, Osaka, Shizuoka, Tokyo
2017-10-30
Active, closed
Takara Bio Inc.
Phase 1
36
Nagoya, Chiba, Kashiwa, Yokohama, Osaka, Chūōku, Koto-Ku
2017-09-25
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Suita, Shizuoka, Okayama, Osaka
2017-08-23
Active, closed
Pfizer
Phase 3
296
Nagoya, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai, Osaka
2017-04-27
Active, closed
Acerta Pharma BV
Phase 3
635
Fukuoka, Kobe, Kyoto, Matsuyama, Nagoya, Osaka, Sapporo, Sendai
2017-04-05
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Tōon, Sapporo, Yokohama, Osaka, Chuo-ku, Yonago, Kashiwa, Nagoya
2017-03-07
Active, closed
ViiV Healthcare
Phase 3
631
Aichi, Osaka, Tokyo
2016-10-27
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Fukuoka, Kashiwa-shi, Kitaadachi-gun, Kurume-shi, Matsuyama, Nagoya, Niigata, Osaka
2016-09-13
Active, closed
W.L.Gore & Associates
Not applicable
79
Aichi, Osaka, Ōita, Tokyo
2016-08
Recruiting
International Intracranial Dissection Study
NCT02756091Cerebrovascular Disorders, Vascular: Intracranial, Intimal Dissection, Stroke
Insel Gruppe AG, University Hospital Bern
Observational
500
Osaka
2016-08
Recruiting
Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
NCT02781922Hypoplastic Left Heart Syndrome, Single Ventricle
Metcela Inc.
Phase 3
40
Kanagawa, Okayama, Osaka, Shizuoka
2016-06
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Chūōku, Hyōgo, Kashiwa, Kurume, Nagoya, Niigata, Osaka, Tokyo
2016-05-24
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Topotecan·Taxol
National Cancer Institute (NCI)
Phase 2/3
582
Tōon, Sapporo, Kagoshima, Koto-ku, Osaka, Saitama, Tokyo
2016-05-03
Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
DrugsConvalescent plasma·Repagermanium·Ivermectin·Telmisartan
UMC Utrecht
Phase 3
20,000
Kawasaki, Yokohama, Minami, Osaka, Tokyo, Wakayama
2016-04-11
Active, closed
Hoffmann-La Roche
Phase 2
534
Aichi, Chūō, Hyōgo, Matsuyama, Miyagi, Niigata, Osaka, Shizuoka
2015-11-19
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
5,796
Nagoya, Sapporo, Chiba, Kyoto, Osaka
2015-08
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Nagoya, Sapporo, Isehara, Suita, Bunkyo Ku, Fukuoka, Osaka
2015-03-05
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Partner Therapeutics, Inc.
Phase 2
250
Chūōku, Kawasaki, Osaka, Tokyo
2015-01
Recruiting
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817Alzheimer's Disease
Washington University School of Medicine
Observational
700
Niigata, Osaka, Tokyo
2009-01
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Kobe, Nankoku, Chiba, Niigata, Osaka, Tokyo
2001-07-31
Recruiting
Manuel Monreal
Observational
120,000
Kitakyushu, Maebashi, Amagasaki, Kumamoto, Kyoto, Tsu, Nagasaki, Osaka
2001-03
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Yonago, Chiba, Osaka, Tokyo
1991-04-01
Rows per page Showing 1–354 of 354
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-japan/city/osaka

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 354 of those studies with a site in Osaka.

How many clinical trials are recruiting in Osaka?

165 of the 354 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 179 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Osaka), 354 studies
PhaseStudiesRecruitingShare
Phase 31717548.3%
Phase 2692919.5%
Observational34219.6%
Phase 12396.5%
Phase 1/223156.5%
Phase 2/31464%
Not applicable1263.4%
Phase 4842.3%

Most active sponsors

Lead sponsors with the most studies (Osaka)
Lead sponsorStudiesRecruiting
GlaxoSmithKline1912
AstraZeneca187
Eli Lilly and Company1710
Pfizer167
AbbVie148
Novartis Pharmaceuticals143
Hoffmann-La Roche123
Janssen Research & Development, LLC123
Merck Sharp & Dohme LLC114
Takeda98
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.